Press releases

GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, April 30, 2024 – 6.30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the post-acute sequelae of COVID-19 (PASC, long COVID or post-COVID), reported today its full-year results for the year ended December 31, 2023, and provided a corporate update.

GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting

Geneva, Switzerland, March 20, 2024 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its Extraordinary General Meeting (EGM) of March 18, 2024.

https://geneuro.ch/data/news/GeNeuro_EGM-20032024-EN-v2.pdf

GeNeuro announces the availability of a prospectus for the listing of new shares on Euronext Paris

Geneva, Switzerland, February 2, 2024 – 20:00 CEST – GeNeuro (Euronext Paris : CH0308403085 – GNRO) (the “Company”), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the post-acute sequelae of COVID-19 (PASC, COVID long or post-COVID), announces that on February 2, 2024, the Autorité des marchés financiers (the “AMF”) approved an admission prospectus under number 24-016 (the “Prospectus”) in connection with the admission to trading on the regulated market of Euronext Paris of 4.666,901 new ordinary bearer shares of the Company issued following a capital increase of 5 million euros with cancellation of preferential subscription rights carried out as part of (i) an international private placement reserved for specialized and strategic investors of 4.666,901 new ordinary bearer shares (the “International Private Placement”) and (ii) a separate public offering to retail investors via the PrimaryBid platform in France of 95,004 new ordinary bearer shares (together with the International Private Placement, the “Offering”).

Français: https://geneuro.ch/data/news/Geneuro-CP-norme-de-mise-a-dispo-prospectus-02.02.2024.pdf

GeNeuro announces a successful €5 million private placement

Geneva, Switzerland,  February 2, 2024 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the successful completion of a €5 million capital increase with cancellation of the preferential subscription rights through an international private placement reserved for specialized or strategic investors of (the “Private Placement”) 4,666,901 new ordinary bearer shares of GeNeuro and through a public offering for retail investors in France via the PrimaryBid platform (the “PrimaryBid Offer”, and together with the Private Placement, the “Offering”) of 95,004 new ordinary bearer shares of GeNeuro. All new ordinary shares have a par value of CHF 0.05 each (the “New Shares”).

https://geneuro.ch/data/news/PR-GeNeuro-Closes-Financing-ENG-02.02.2024.pdf

GeNeuro Reports 2023 Half-Year Results and Provides Corporate Update

Geneva, Switzerland, September 29, 2023, at 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today reported its half-year financial results for the period ending June 30, 2023 and provided a corporate update.

https://geneuro.ch/data/news/GeNeuro-PR-1H2023-Results-ENG-02.10.2023.pdf

GeNeuro: financial information for the second quarter 2023

Geneva, Switzerland, July 25, 2023 – 6.00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today reported on its 2023 second quarter cash position.

https://geneuro.ch/data/news/GeNeuro-PR-Q2-2023-EN.pdf